Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

• Status: Terminated
• Trial end date: 1969-12-31

Summary

Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two different doses of TPV in combination with RTV for efficacy and safety.

• Phase: Phase 2

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: HIV Protease Inhibitors; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Tipranavir